Vaccinex, Inc.
Vaccinex, Inc. (VCNX) Stock Overview
Explore Vaccinex, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.6M
P/E Ratio
-0.11
EPS (TTM)
$-8.88
ROE
18.55%
VCNX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Vaccinex, Inc. (VCNX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 59.29, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.09.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.11 and a market capitalization of 2.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Maurice Zauderer
23
1895 Mount Hope Avenue, Rochester, NY
2018